In vivo gene therapy is already an established clinical reality. Approved treatments such as Zolgensma, Luxturna and Hemgenix demonstrate the potential of delivering genetic material directly into the body to treat disease. However, generating engineered therapeutic cells inside the patient, including in vivo CAR-T, remains an emerging and investigational approach.
Big pharma is placing its bets
The commercial interest in in vivo approaches is becoming increasingly difficult to ignore. Over the past year, several major pharmaceutical companies have made significant investments in technologies designed to advance in vivo gene delivery and cell engineering.
Bristol Myers Squibb announced its acquisition of Orbital Therapeutics for $1.5 billion in October 2025, gaining access to its RNA-based in vivo CAR-T platform. In February 2026, Eli Lilly announced its acquisition of Orna Therapeutics for up to $2.4 billion, combining circular RNA with novel LNP delivery technology. Lilly subsequently completed its acquisition of Kelonia Therapeutics in Q2 2026, following an agreement worth up to $7 billion, including $3.25 billion upfront, for its lentiviral in vivo CAR-T platform. More recently, Johnson & Johnson announced a strategic collaboration with Sail Biomedicines in July 2026, involving $785 million in initial payments and an exclusive option to acquire the company for a further $2.58 billion.
These transactions highlight the industry's growing interest in platform capabilities as well as individual candidates. They also demonstrate that there is no single established approach, with both viral and non-viral delivery technologies attracting substantial investment.
Could successful in vivo CAR-T fundamentally change the economics and accessibility of cell therapy?
"In vivo CAR-T could fundamentally transform cell therapy by eliminating patient-specific manufacturing, reducing costs, and expanding access beyond specialized centers into community care. It could also reach patients who are poor candidates for conventional CAR-T, including those with autoimmune diseases for whom lymphodepleting chemotherapy and chronic B cell aplasia poses unacceptable risks, or patients whose cells fail ex vivo manufacturing. Its greatest impact may be making the curative potential of cell therapy accessible to a much broader patient population.” Michael Klichinsky, CSO, Nava Therapeutics
What changes if in vivo works?
The implications extend beyond the treatment itself. A shift towards in vivo approaches could reshape the underlying CGT manufacturing model. Reducing dependence on patient-specific cell collection, modification and reinfusion could simplify production workflows, reduce logistical complexity and support more standardised manufacturing processes with the potential for greater scalability.
There are also potential implications for cost and patient access. Simpler administration and reduced reliance on individualised manufacturing could help expand treatment availability beyond highly specialised centres and reach more patients. However, in vivo does not automatically mean cheaper therapies. Vector production, delivery technologies, dosing, safety monitoring and manufacturing quality will remain significant considerations.
Gene delivery: The critical enabler
Realising this potential depends on overcoming one of the industry's most significant challenges: delivering the right genetic payload to the right cells, in the right tissue, safely and consistently.
Tissue and cell targeting specificity, delivery efficiency, immunogenicity, off-target effects and the potential for repeat dosing all remain important challenges. While AAV and lentiviral vector platforms continue to evolve, non-viral technologies such as LNPs and other emerging delivery systems are opening up alternative possibilities.
What needs to happen for next-generation viral vectors to become safer, more scalable and commercially viable?
“In vivo gene therapy is already a proven clinical reality for several other advanced therapies. Extending this approach to CAR-T cell engineering represents an exciting development with the potential to fundamentally transform how these therapies are developed, manufactured, and delivered. However, whether this approach can meaningfully simplify manufacturing workflows, reduce costs and development timelines, and streamline regulatory pathways remains to be demonstrated.”
What happens next?
Despite the growing investment and scientific progress, significant questions remain around clinical efficacy, long-term safety, delivery specificity, manufacturing consistency and commercial viability. The transition towards in vivo is not guaranteed, but its potential is becoming an increasingly important consideration in the future development of advanced therapies.
As the field evolves, innovation will be shaped as much by how therapies are delivered as by the genetic payloads themselves.
Explore the future of in vivo gene therapy at Phacilitate Advanced Therapies Week 2027, including the Innovation in Gene Delivery track, where industry leaders will examine the technologies, challenges and commercial opportunities shaping the next generation of advanced therapies.